## Supporting Information for

## Copper(II)-Promoted Oxidative C-H/C-H Cross-Coupling for A Rapid Access to Aza-BODIPY-indole Derivatives with Broad Optical Absorption

Ruyong Jiang, Xiuguang Yang, Di Wu\*

Key Laboratory of Green Chemistry and Technology of Ministry of Education, College of

Chemistry, Sichuan University, 29 Wangjiang Road, Chengdu 610064, P.R. China

Tel: 86-28-85412285; E-mail: wood@scu.edu.cn.

## **Table of Contents**

I. General remarks	S2
II. Synthesis and characterization	
III. UV-vis-NIR absorption spectra	S14
IV. DFT Computational detail	S19
V. Electrochemical properties	S24
VI. Reference	S25
VIII. Copies of NMR spectra	S26

#### I. General remarks

<sup>1</sup>H (400 MHz) and <sup>13</sup>C (100 MHz) NMR spectra were recorded on Agilent 400-MR DD2 spectrometer. The <sup>1</sup>H NMR chemical shifts were measured relative to CDCl<sub>3</sub>, CD<sub>3</sub>CN or TMS as internal reference (CDCl<sub>3</sub>:  $\delta = 7.26$  ppm; CD<sub>3</sub>CN:  $\delta = 1.94$  ppm; TMS:  $\delta = 0.00$  ppm). The <sup>13</sup>C NMR chemical shifts were given using CDCl<sub>3</sub> as internal standard (CDCl<sub>3</sub>:  $\delta = 77.16$  ppm). High-resolution mass spectra (HRMS) were obtained with Waters-Q-TOF-Premier (ESI). Melting points were measured with SGW®X-4/4A/4B and uncorrected. Absorption spectra were detected on HITACHI U-2910 absorption spectrophotometer. Cyclic voltammetries (CV) were performed on LK2005A at a scan rate of 50 mV·s<sup>-1</sup> in dry CH<sub>3</sub>CN solution of compounds containing 0.10 M of *tetra-n*-butylammonium hexafluorophosphate (TBAPF<sub>6</sub>) as the supporting electrolyte. Ag/Ag<sup>+</sup> (0.01 M of AgNO<sub>3</sub> in CH<sub>3</sub>CN) was employed as a reference electrode. A platinum wire was used as a counter electrode and a platinum plate as a working electrode. Energy levels were calculated with respect to a standard ferrocene/ferrocenium (Fc/Fc<sup>+</sup>) redox couple as an external reference.

Unless otherwise noted, all reagents were obtained from commercial suppliers and used without further purification. Anhydrous solvents were freshly distilled from  $CaH_2$  (dimethylsulfoxide (DMSO), dimethylformimide (DMF), acetonitrile (CH<sub>3</sub>CN), dichloroethane(DCE)) or sodium/benzophenone (toluene, tetrahydrofuran (THF)) before using. TBAPF<sub>6</sub> was recrystallized from ethanol and further dried under vacuum for 48 h. All syntheses and manipulations were carried out under an  $N_2$  atmosphere.

TBAF: tetrabutylammonium fluoride; TBAC: tetrabutylammonium chloride; TBAB: tetrabutylammonium bromide; TBAI: tetrabutylammonium iodide.

#### **II.** Synthesis and characterization

#### i) Synthesis of aza-BODIPYs



Scheme S1 Synthetic routes toward aza-BODIPYs. Intermediates 1 and 2 were prepared according to the literatures<sup>S1</sup>.

**Compound 3a: 2a** (13.46 g, 50 mmol), ammonium acetate (96.31 g, 1.25 mol) and ethanol (250 mL) were heated under reflux for 24 h. During the reaction, the intermediate product precipitated as a blue-black solid. The reaction was allowed to cool to room temperature and solid was filtered and washed with ethanol. After the intermediate product was dried by vacuum oven at 40 °C, it was dissolved in toluene (150 mL). Diisopropylethylamine (DIPEA, 19.83 mL, 120 mmol) and boron trifluoride diethyl etherate (BF<sub>3</sub>•OEt<sub>2</sub>, 19.75 mL, 160 mmol) were added and then the mixture was refluxed for 3 h. The mixture was washed with water and the organic layer was collected, dried over Na<sub>2</sub>SO<sub>4</sub> and evaporated under vacuum. The residue was washed by hot ethanol twice to give the product as a metallic brown solid. Yield: 7.96 g (32%). M.p.: 231.7-232.2 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  = 8.02-8.08(m, 8H), 7.40-7.55(m, 12H), 7.04(s, 2H) ppm. <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta$  = 119.3, 128.75, 128.78, 129.5, 129.66, 129.7, 129.8, 131.1, 131.7, 132.4, 144.3, 159.7 ppm. HRMS (ESI<sup>+</sup>): calcd for C<sub>32</sub>H<sub>22</sub>BF<sub>2</sub>N<sub>3</sub>Na [M+Na]<sup>+</sup> 520.1773, found 520.1771.

**Compound 3b:** The synthetic procedure was the same as **3a**. **2b** (14.96 g, 50 mmol) was used instead of **2a**. **3b** was given as a metallic red solid. Yield: 9.50 g (34 %). M.p.: 201.1-201.7 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$ = 3.89 (s, 6H), 6.01-7.04 (m, 6H), 7.44-7.46 (m, 6H), 8.06-8.10 (m, 8H) ppm. <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta$ = 55.6, 114.4, 118.8, 124.3, 128.7, 129.35, 129.41, 131.8, 132.6, 143.3, 145.5, 158.3, 162.0 ppm. HRMS (ESI<sup>+</sup>): calcd for C<sub>32</sub>H<sub>27</sub>BF<sub>2</sub>N<sub>3</sub>O<sub>2</sub> [M+H]<sup>+</sup> 580.1984, found 580.1976.

#### ii) Synthesis of aza-BODIPYs derivatives

#### 1) Optimization of Copper(II)-Promoted Oxidative C-H/C-H Cross-Coupling

A 25 mL Schlenk tube with a magnetic stir bar was charged with **3a** (0.20 mmol), indole (0.60 mmol, 3.0 equiv.), metal source (20 mol%), ligand (50 mol%) and additive/oxidant (2.0 equiv.). The system was evacuated twice and back filled with N<sub>2</sub>. Next, the solvent was added via a syringe and the rubber septum was replaced with a glass stopper under N<sub>2</sub>. Then the reaction mixture was stirred at the indicated temperature for 2-24 h in an oil bath. After the reaction mixture was cooled to ambient temperature, the solvent was filtered through a celite pad, and then washed with CH<sub>2</sub>Cl<sub>2</sub> (20-30 mL). The combined filtrate was concentrated and purified via column chromatography on silica gel (200-300 mesh) to provide the desired products.

Table S1. Optimization of the direct C–H/C–H arylation of aza-BODIPY 3a with indole<sup>*a*</sup>



<b>F 4</b>		Lizand	Additive		time (h)	Isolated yield	
Entry	[WI] source	Ligand	/Oxidant	Solvent	time (n)	$(5a + 5b) / \%^{b}$	
1	Pd(OAc) <sub>2</sub>	2,2'-bipyridine	Ag <sub>2</sub> CO <sub>3</sub>	toluene	12	15 (15+ trace)	
2	$Pd(OAc)_2$	PPh <sub>3</sub>	Cu(OAc) <sub>2</sub>	toluene	12	14 (9+5)	
3	Pd(CF <sub>3</sub> COO) <sub>2</sub>	2,2'-bipyridine	Ag <sub>2</sub> CO <sub>3</sub>	toluene	12	30 (20+10)	
4	CuBr <sub>2</sub>	2,2'-bipyridine	Ag <sub>2</sub> CO <sub>3</sub>	toluene	12	28 (13+15)	
5	CuO	2,2'-bipyridine	Ag <sub>2</sub> CO <sub>3</sub>	toluene	12	28 (21+17)	
6	CuI	2,2'-bipyridine	Ag <sub>2</sub> CO <sub>3</sub>	toluene	12	39 (25+14)	
7	Cu(OAc) <sub>2</sub>	2,2'-bipyridine	Ag <sub>2</sub> CO <sub>3</sub>	dioxane	12	ND <sup>c</sup>	

8	Cu <sub>2</sub> (OH) <sub>2</sub> CO <sub>3</sub>	2,2'-bipyridine	Cu(OAc) <sub>2</sub>	CH <sub>3</sub> CN/toluene (1:1)	12	43(20+23)
$9^d$	Cu(OAc) <sub>2</sub>	2,2'-bipyridine	/	CH <sub>3</sub> CN/dioxane (1:1)	12	17 (7+10)
$10^d$	Cu(OAc) <sub>2</sub>	2,2'-bipyridine	/	CH <sub>3</sub> CN/DCE (1:1)	12	$ND^{c}$
11 <sup><i>d</i></sup>	Cu(OAc) <sub>2</sub>	2,2'-bipyridine	TBAB	CH <sub>3</sub> CN/DCE (1:1)	12	52 (32+20)
12 <sup><i>d</i></sup>	Cu(OAc) <sub>2</sub>	2,2'-bipyridine	TBAC	CH <sub>3</sub> CN/DCE (1:1)	12	$ND^{c}$
13 <sup><i>d</i></sup>	Cu(OAc) <sub>2</sub>	2,2'-bipyridine	TBAI	CH <sub>3</sub> CN/DCE (1:1)	12	36 (17+19)
14 <sup><i>d</i></sup>	Cu(OAc) <sub>2</sub>	2,2'-bipyridine	TBAF	CH <sub>3</sub> CN/DCE (1:1)	12	68 (30+38)
15 <sup><i>d</i></sup>	Cu(OAc) <sub>2</sub>	PPh <sub>3</sub>	TBAF	CH <sub>3</sub> CN/DCE (1:1)	12	25 (14+10)
16 <sup><i>d</i></sup>	Cu(OAc) <sub>2</sub>	Pcy <sub>3</sub> •HBF <sub>4</sub>	TBAF	CH <sub>3</sub> CN/DCE (1:1)	12	28 (15+13)
$17^d$	Cu(OAc) <sub>2</sub>	P <sup>t</sup> Bu <sub>3</sub> •HBF <sub>4</sub>	TBAF	CH <sub>3</sub> CN/DCE (1:1)	12	trace
18 <sup><i>d</i></sup>	Cu(OAc) <sub>2</sub>	2,2'-bipyridine	TBAF	CH <sub>3</sub> CN/DCE (1:1)	24	66 (34+32)
19 <sup><i>d</i></sup>	Cu(OAc) <sub>2</sub>	2,2'-bipyridine	TBAF	CH <sub>3</sub> CN/DCE (1:1)	6	77 (35+42)
<b>20</b> <sup><i>d</i></sup>	Cu(OAc) <sub>2</sub>	2,2'-bipyridine	TBAF	CH <sub>3</sub> CN/DCE (1:1)	2	83 (34+49)
21 <sup><i>d</i></sup>	Cu(OAc) <sub>2</sub>	2,2'-bipyridine	TBAF	CH <sub>3</sub> CN/DCE (1:1)	0.5	68 (45+23)
22 <sup><i>d,e</i></sup>	Cu(OAc) <sub>2</sub>	2,2'-bipyridine	TBAF	CH <sub>3</sub> CN/DCE (1:1)	2	60 (23+37)
23 <sup><i>d,f</i></sup>	Cu(OAc) <sub>2</sub>	2,2'-bipyridine	TBAF	CH <sub>3</sub> CN/DCE (1:1)	2	36 (11+25)
24 <sup><i>d</i>,g</sup>	Cu(OAc) <sub>2</sub>	2,2'-bipyridine	TBAF	CH <sub>3</sub> CN/DCE (1:1)	2	28 (7+21)

<sup>*a*</sup>Reaction conditions: **3a** (0.20 mmol), indole (0.60 mmol), palladium source (20 mol%) or copper source (20 mol%) ligand (50 mol%), additive (0.40 mmol) and solvent (1.0 mL) at 120 °C and reaction time under N<sub>2</sub> atmosphere, unless otherwise noted. <sup>*b*</sup>Total yield with **5a** and **5b** inside parenthesis. <sup>*c*</sup>not detected. <sup>*d*</sup>Cu(OAc)<sub>2</sub> (0.60 mmol). <sup>*e*</sup>100 °C. <sup>*f*</sup>80 °C. <sup>*g*</sup>60 °C.

 $PCy_3 \cdot HBF_4 = tricyclohexylphosphonium, P'Bu_3 \cdot HBF_4 = tri-tert-butyphosphine tetrafluoroborate.$ 

# 2) General procedure for direct C-H/C-H arylation of aza-BODIPYs with indoles

A 25 mL Schlenk tube with a magnetic stirbar was charged with **3a** or **3b** (0.20 mmol), indoles (3.0 equiv.),  $Cu(OAc)_2$  (109.0 mg, 3.0 equiv.), 2,2'-bipyridine (15.6 mg, 50 mol%), TBAF (104.6 mg, 2.0 equiv.). The system was evacuated twice and back filled with N<sub>2</sub>. Then, DCE (0.5 mL) and CH<sub>3</sub>CN (0.5 mL) was added via a syringe and the rubber septum was replaced with a stopper under N<sub>2</sub>. Then the reaction mixture was stirred at 120 °C for 2 h in an oil bath. After the reaction mixture

was cooled to ambient temperature, the solvent was removed under reduced pressure. The solvent was filtered through a Celite pad, and then washed with 20-30 mL of  $CH_2Cl_2$ . The combined filtrates were concentrated and purified via column chromatography on silica gel (200-300 mesh) to provide the desired products.



Following the general procedure, the mixture of **aza-BODIPY 3a** (99.4 mg, 0.20 mmol), indole (70.24 mg, 0.60 mmol), Cu(OAc)<sub>2</sub> (109.0 mg, 3.0 equiv.), 2,2'-bipyridine (15.6 mg, 50 mol%), TBAF (104.6 mg, 2.0 equiv.), DCE (0.5 mL) and CH<sub>3</sub>CN (0.5 mL) was stirred at 120 °C for 2 h. Purification via column chromatography on silica gel (Ethyl acetate/petroleum ether/dichloromethane = 1/10/1 to 1/4/1, v/v) afforded the monoarylated product **5a** (41.6 mg) in 34% yield and the diarylated product **5b** (71.3 mg) in 49% yield.

**5a**: A brown solid with metallic lustre. M.p.: >250 °C.<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta = 6.70$  (s, 1H), 6.85 (t, J = 8.0 Hz, 1H), 6.93 (d, J = 8.0 Hz, 1H), 7.04 (s, 1H), 7.10 (t, J = 8.0 Hz, 1H), 7.24-7.26 (m, 5H), 7.30 (d, J = 8.0 Hz, 2H), 7.41-7.44 (m, 6H), 7.53 (d, J = 8.0 Hz, 2H), 7.61 (d, J = 8.0 Hz, 2H), 8.00-8.01 (m, 2H), 8.11-8.12 (m, 3H) ppm. HRMS (ESI<sup>+</sup>): calcd for C<sub>40</sub>H<sub>28</sub>BF<sub>2</sub>N<sub>4</sub> [M+H]<sup>+</sup> 613.2375, found 613.2372.

**5b**: A wine-red solid. M.p.: >250 °C.<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$ = 6.70 (s, 2H), 6.85 (t, *J*= 8.0 Hz, 2H), 6.96 (d, 8.0 Hz, 2H), 7.10 (t, *J*= 8.0 Hz, 2H), 7.18-7.21 (m, 12H), 7.30 (d, *J*= 8.0 Hz, 2H), 7.49 (d, *J*= 8.0 Hz, 4H), 7.63 (d, *J*= 8.0 Hz, 4H), 8.09 (s, 2H) ppm. HRMS (ESI<sup>+</sup>): calcd for C<sub>48</sub>H<sub>33</sub>BF<sub>2</sub>N<sub>5</sub> [M+H]<sup>+</sup> 728.2797, found

#### 728.2792.





Following the general procedure, the mixture of **aza-BODIPY 3a** (99.4 mg, 0.20 mmol), 5-methoxyindole (88.3 mg, 0.60 mmol), Cu(OAc)<sub>2</sub> (109.0 mg, 3.0 equiv.), 2,2'-bipyridine (15.6 mg, 50 mol%), TBAF (104.6 mg, 2.0 equiv.), DCE (0.5 mL) and CH<sub>3</sub>CN (0.5 mL) was stirred at 120 °C for 2 h. Purification via column chromatography on silica gel (Ethyl acetate/petroleum ether/dichloromethane = 1/10/1 to 1/4/1, v/v) afforded the monoarylated product **6a** (56.5 mg) in 44% yield and the diarylated product **6b** (75.6 mg) in 48% yield.

**6a**: A brown solid with a metallic lustre. M.p.: 202.2-202.8 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$ = 3.42 (s, 3H), 6.29 (s, 1H), 6.61 (s, 1H), 6.73 (d, *J*= 8.0 Hz, 1H), 7.03 (s, 1H), 7.16 (d, *J*= 8.0 Hz, 1H), 7.26-7.29 (m, 5H), 7.34 (d, *J*= 4.0 Hz, 1H), 7.41-7.44(m, 6H), 7.55 (d, *J*= 8.0 Hz, 2H), 7.63 (d, *J*= 8.0 Hz, 2H), 7.99-8.01 (m, 3H), 8.12 (d, *J*= 8.0 Hz, 2H) ppm. HRMS (ESI<sup>+</sup>): calcd for C<sub>41</sub>H<sub>30</sub>BF<sub>2</sub>N<sub>4</sub>O [M+H]<sup>+</sup> 643.2481, found 643.2493.

**6b**: A wine-red solid. M.p.: >250 °C.<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$ = 3.43 (s, 6H), 6.31 (s, 2H), 6.62 (s, 2H), 6.73 (d, *J*= 8.0 Hz, 2H), 7.16-7.24 (m, 12H), 7.26-7.31 (m, 2H), 7.51 (d, *J*= 8.0 Hz, 4H), 7.64 (d, *J*= 8.0 Hz, 4H), 7.98 (s, 2H) ppm. HRMS (ESI<sup>+</sup>): calcd for C<sub>50</sub>H<sub>37</sub>BF<sub>2</sub>N<sub>5</sub>O<sub>2</sub> [M+H]<sup>+</sup> 788.3008, found 788.3001.



Following the general procedure, the mixture of **aza-BODIPY 3a** (99.4 mg, 0.20 mmol), 5-methylindole (78.7 mg, 0.60 mmol), Cu(OAc)<sub>2</sub> (109.0 mg, 3.0 equiv.), 2,2'-bipyridine (15.6 mg, 50 mol%), TBAF (104.6 mg, 2.0 equiv.), DCE (0.5 mL) and CH<sub>3</sub>CN (0.5 mL) was stirred at 120 °C for 2 h. Purification via column chromatography on silica gel (Ethyl acetate/petroleum ether/dichloromethane = 1/10/1 to 1/4/1, v/v) afforded the monoarylated product **7a** (75.2 mg) in 60% yield and the diarylated product **7b** (51.4 mg) in 34% yield.

**7a**: A brown solid with a metallic lustre. M.p.: 224.7-225.4 °C.<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$ = 2.17 (s, 3H), 6.62 (s, 1H), 6.68 (s, 1H), 6.91 (d, *J*= 8.0 Hz, 1H), 7.03(s, 1H), 7.15 (d, *J*= 8.0 Hz, 1H), 7.24-7.26 (m, 4H), 7.29-7.31 (m, 2H), 7.42-7.44 (m, 6H), 7.55 (d, *J*= 8.0 Hz, 2H), 7.63(d, *J*= 8.0 Hz, 2H), 7.97-8.01 (m, 3H), 8.13 (d, *J*= 8.0 Hz, 2H) ppm. HRMS (ESI<sup>+</sup>): calcd for C<sub>41</sub>H<sub>29</sub>BF<sub>2</sub>N<sub>4</sub>Na [M+Na]<sup>+</sup> 649.2351, found 649.2353.

**7b**: A wine-red solid. M.p.: >250 °C.<sup>1</sup>H NMR (400 MHz, CDCl3):  $\delta$ = 2.17 (s, 6H), 6.65 (s, 2H), 6.70 (s, 2H), 6.91 (d, *J*= 8.0 Hz, 2H), 7.17-7.21 (m, 14H), 7.50 (d, *J*= 8.0 Hz, 4H), 7.63 (d, *J*= 8.0 Hz, 4H), 7.98 (s, 2H) ppm. HRMS (ESI<sup>+</sup>): calcd for C<sub>50</sub>H<sub>36</sub>BF<sub>2</sub>N<sub>5</sub>Na [M+Na]<sup>+</sup> 778.2930, found 778.2938.



Following the general procedure, the mixture of **aza-BODIPY 3a** (99.4 mg, 0.20 mmol), 5-bromoindole (117.6 mg, 0.60 mmol), Cu(OAc)<sub>2</sub> (109.0 mg, 3.0 equiv.), 2,2'-bipyridine (15.6 mg, 50 mol%), TBAF (104.6 mg, 2.0 equiv.), DCE (0.5 mL) and CH<sub>3</sub>CN (0.5 mL) was stirred at 120 °C for 2 h. Purification via column chromatography on silica gel (Ethyl acetate/petroleum ether/dichloromethane = 1/10/1 to 1/2/1, v/v) afforded the monoarylated product **8a** (60.73 mg) in 44% yield and the diarylated product **8b** (86.5 mg) in 49% yield.

**8a**: A brown solid. M.p.: >250 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$ = 6.72 (s, 1H), 7.06 (s, 1H), 7.06 (s, 1H), 7.17 (s, 2H), 7.26-7.35 (m, 6H), 7.42-7.45 (m, 6H), 7.52 (d, *J*= 8.0 Hz, 2H), 7.58 (d, *J*= 8.0 Hz, 2H), 8.01 (bs, 2H), 8.11-8.13 (m, 3H) ppm. HRMS (ESI<sup>-</sup>): calcd for C<sub>42</sub>H<sub>26</sub>BBrF<sub>2</sub>N<sub>4</sub>Na [M+Na]<sup>+</sup> 713.1300, found 713.1304.

**8b**: A brown solid. M.p.: >250 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$ = 6.71 (s, 2H), 7.03 (s, 2H), 7.17 (bs, 4H), 7.20-7.23 (m, 8H), 7.26 (bs, 4H), 7.48 (d, *J*= 8.0 Hz, 4H), 7.59 (d, *J*= 8.0 Hz, 4H), 8.11 (s, 2H) ppm. HRMS (ESI<sup>+</sup>): calcd for C<sub>48</sub>H<sub>30</sub>BBr<sub>2</sub>F<sub>2</sub>N<sub>5</sub>Na [M+Na]<sup>+</sup> 908.0806, found 908.0804.





Following the general procedure, the mixture of **aza-BODIPY 3a** (99.4 mg, 0.20 mmol), 5-cyanoindole (78.7 mg, 0.60 mmol),  $Cu(OAc)_2$  (109.0 mg, 3.0 equiv.), 2,2'-bipyridine (15.6 mg, 50 mol%), TBAF (104.6 mg, 2.0 equiv.), DCE (0.5 mL) and CH<sub>3</sub>CN (0.5 mL) was stirred at 120 °C for 2 h. Purification via column chromatography on silica gel (Ethyl acetate/petroleum ether/dichloromethane = 1/10/1 to 1/2/1, v/v) afforded the monoarylated product **9a** (35.7 mg) in 28% yield and the diarylated product **9b** (15.5 mg) in 10% yield.

**9a**: A black solid. M.p.: >250 °C.<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$ = 6.82 (s, 1H), 7.08 (s, 1H), 7.22-7.26 (m, 5H), 7.28-7.32 (m, 4H), 7.43-7.46 (m, 6H), 7.49 (d, *J*= 8.0 Hz, 2H), 7.54(d, *J*= 8.0 Hz, 2H), 8.02 (bs, 2H), 8.11-8.13 (m, 2H), 8.38 (s, 1H) ppm. HRMS (ESI<sup>-</sup>): calcd for C<sub>41</sub>H<sub>25</sub>BF<sub>2</sub>N<sub>5</sub> [M-H]<sup>-</sup> 636.2171, found 636.2173.

**9b**: A black solid. M.p.: >250 °C. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>CN):  $\delta$  = 7.11 (d, *J* = 4.0 Hz, 2H), 7.24-7.35 (m, 14H), 7.37 (s, 2H), 7.45-7.49 (t, *J* = 8.0 Hz, 6H), 7.56 (d, *J* = 1.6 Hz, 2H), 7.57 (d, *J* = 1.6 Hz, 2H), 9.75 (s, 2H) ppm. HRMS (ESI<sup>+</sup>): calcd for C<sub>50</sub>H<sub>30</sub>BF<sub>2</sub>N<sub>7</sub>Na [M+Na]<sup>+</sup> 800.2522, found 800.2523.





Following the general procedure, the mixture of **aza-BODIPY 3a** (99.4 mg, 0.20 mmol), 2-methylindole (78.7 mg, 0.60 mmol), Cu(OAc)<sub>2</sub> (109.0 mg, 3.0 equiv.), 2,2'-bipyridine (15.6 mg, 50 mol%), TBAF (104.6 mg, 2.0 equiv.), DCE (0.5 mL) and CH<sub>3</sub>CN (0.5 mL) was stirred at 120 °C for 2 h. Purification via column chromatography on silica gel (Ethyl acetate/petroleum ether/dichloromethane = 1/10/1 to 1/4/1, v/v) afforded the monoarylated product **10a** (68.9 mg) in 55% yield and the diarylated product **10b** (58.9 mg) in 39% yield.

**10a**: A bronw solid with a gold metalliclustre. M.p.: 203.7-204.5 °C.<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$ = 1.81 (s, 3H), 6.85 (t, *J*= 8.0 Hz, 1H), 6.97 (d, *J*= 8.0 Hz, 1H), 7.03-7.05 (m, 2H), 7.19-7.26 (m, 7H), 7.43-7.45(m, 6H), 7.53 (d, *J*= 8.0 Hz, 2H), 7.60 (d, *J*= 8.0 Hz, 2H), 7.84 (s, 1H), 8.02 (s, 2H), 8.14 (d, *J*= 4.0 Hz, 2H) ppm. HRMS (ESI<sup>+</sup>): calcd for C<sub>41</sub>H<sub>29</sub>BF<sub>2</sub>N<sub>4</sub>Na [M+Na]<sup>+</sup> 649.2351, found 649.2346.

**10b**: A wine-red solid. M.p.: >250 °C.<sup>1</sup>H NMR (400 MHz, CDCl3):  $\delta$  = 1.81 (s, 6H), 6.86-6.88 (m, 2H), 6.97 (bs, 2H), 7.04 (t, *J* = 8.0 Hz, 2H), 7.15-7.21 (m, 14H), 7.49 (d, *J* = 8.0 Hz, 4H), 7.63 (d, *J* = 4.0 Hz, 4H), 7.83 (s, 2H) ppm. HRMS (ESI<sup>+</sup>): calcd for C<sub>50</sub>H<sub>36</sub>BF<sub>2</sub>N<sub>5</sub> [M+Na]<sup>+</sup> 778.2930, found 778.2925.





Following the general procedure, the mixture of **aza-BODIPY 3b** (111.5 mg, 0.20 mmol), 5-methoxyindole (88.3 mg, 0.60 mmol), Cu(OAc)<sub>2</sub> (109.0 mg, 3.0 equiv.), 2,2'-bipyridine (15.6 mg, 50 mol%), TBAF (104.6 mg, 2.0 equiv.), DCE (0.5 mL) and CH<sub>3</sub>CN (0.5 mL) was stirred at 120 °C for 2 h. Purification via column chromatography on silica gel (Ethyl acetate/petroleum ether/dichloromethane = 1/10/1 to 1/2/1, v/v) afforded the monoarylated product **11a** (60.4 mg) in 43% yield and the diarylated product **11b** (67.8 mg) in 40% yield.

**11a**: A black solid. M.p.: >250 °C.<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$ = 3.44 (s, 3H), 3.79 (s, 3H), 3.87 (s, 3H), 6.33 (s, 1H), 6.67 (s, 1H), 6.75 (d, *J* = 12 Hz, 1H), 6.79 (d, *J* = 18 Hz, 2H), 6.98 (d, *J* = 8.0 Hz, 2H), 7.05 (s, 1H), 7.18-7.26 (m, 4H), 7.40-7.42 (m, 3H), 7.53 (d, *J*= 8.0 Hz, 2H), 7.61 (d, *J* = 4.0 Hz, 2H), 8.00 (s, 1H), 8.05 (d, *J* = 8.0 Hz, 2H), 8.13 (d, *J* = 8.0 Hz, 2H) ppm. HRMS (ESI<sup>-</sup>): calcd for C<sub>43</sub>H<sub>33</sub>BF<sub>2</sub>N<sub>4</sub>O<sub>3</sub>Na [M+Na]<sup>+</sup> 725.2511, found 725.2511.

**11b**: A black solid. M.p.: 212.3-212.9 °C.<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$ = 3.45 (s, 6H), 3.77 (s, 6H), 6.34 (s, 2H), 6.67 (s, 2H), 6.75 (d, *J* = 8 Hz, 6H), 7.19-7.20 (m, 8H), 7.50 (d, *J*= 8.0 Hz, 4H), 7.62 (d, *J*= 4.0 Hz, 4H), 8.00 (s, 2H) ppm. HRMS (ESI<sup>+</sup>): calcd for C<sub>52</sub>H<sub>40</sub>BF<sub>2</sub>N<sub>5</sub>O<sub>4</sub>Na [M+Na]<sup>+</sup> 870.3039, found 870.3043.



Following the general procedure, the mixture of mono-arylated **aza-BODIPY 6a** (64.2 mg, 0.10 mmol), 5-cyanoindole (42.7 mg, 0.30 mmol), Cu(OAc)<sub>2</sub> (54.5 mg, 3.0

equiv.), 2,2'-bipyridine (7.8 mg, 50 mol%), TBAF (52.3 mg, 2.0 equiv.), DCE (0.25 mL) and CH<sub>3</sub>CN (0.25 mL) was stirred at 120 °C for 2 h. Purification via column chromatography on silica gel (Ethyl acetate/petroleum ether/dichloromethane = 1/10/1 to 1/2/1, v/v) afforded the monoarylated product **12** (10.2 mg) in 13% yield.

**12**: A black solid. M.p.: >250 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$ = 3.43 (s, 3H), 6.28 (s, 1H), 6.60 (s, 1H), 6.74 (d, *J*= 8.0 Hz, 1H), 6.80 (s, 1H), 7.16-7.23 (m, 12H), 7.26-7.31(m, 4H), 7.45 (d, *J*= 8.0 Hz, 2H), 7.50-7.54 (m, 4H), 7.64 (d, *J*= 4.0 Hz, 2H), 8.02 (s, 1H), 8.38 (s, 1H) ppm. HRMS (ESI<sup>-</sup>): calcd for C<sub>50</sub>H<sub>32</sub>BF<sub>2</sub>N<sub>6</sub>O [M-H]<sup>-</sup> 781.2699, found 781.2636.



Following the general procedure, the mixture of mono-arylated **aza-BODIPY 6a** (64.2 mg, 0.10 mmol), 2-methylindole (39.4 mg, 0.30 mmol), Cu(OAc)<sub>2</sub> (54.5 mg, 3.0 equiv.), 2,2'-bipyridine (7.8 mg, 50 mol%), TBAF (52.3 mg, 2.0 equiv.), DCE (0.25 mL) and CH<sub>3</sub>CN (0.25 mL) was stirred at 120 °C for 2 h. Purification via column chromatography on silica gel (Ethyl acetate/petroleum ether/dichloromethane = 1/10/1 to 1/2/1, v/v) afforded the monoarylated product **13** (57.1 mg) in 74% yield.

**13**: A black solid. M.p.: 222.3-222.6 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$ = 1.81 (s, 3H), 3.44 (s, 3H), 6.31 (s, 1H), 6.63 (s, 1H), 6.74 (d, *J*= 8 Hz, 1H), 6.83-6.87 (m, 1H), 6.97 (d, *J* = 8 Hz, 1H), 7.04 (t, *J* = 8.0 Hz, 1H), 7.14-7.23 (m, 12H), 7.29-7.30 (m, 2H), 7.47-7.53 (m, 4H), 7.63 (t, *J* = 8.0 Hz, 4H), 7.83 (s, 1H), 7.97 (s, 1H) ppm. HRMS (ESI<sup>+</sup>): calcd for C<sub>50</sub>H<sub>36</sub>BF<sub>2</sub>N<sub>5</sub>ONa [M+Na]<sup>+</sup> 794.2879, found 794.2875.

### III. UV-vis-NIR absorption spectra

Compound	$\lambda^{\text{long}}, \lambda^{\text{short}}/\text{nm}$ ( $\lg \varepsilon^{\text{long}}, \lg \varepsilon^{\text{short}}$ )	$\lambda_{ m cut-off}/ m nm$ $(E_{ m g}^{ m opt}/ m eV)^{a}$	HOMO <sup>cal</sup> /eV <sup>b</sup>	LUMO <sup>cal</sup> /eV <sup>b</sup>
р н р р р р р р р р р р р р р р р р р р	713, 554 (4.3, 4.3)	429-900 1.38	-5.00	-2.89
, N, B, N, B, N, H,	685, 559 (4.4, 4.4)	435-890 1.39	-5.06	-2.92
H <sup>N</sup>	685, 559 (4.5, 4.4)	443-859 1.44	-5.10	-2.94
B H B B B	678, 555 (4.6, 4.4)	433-839 1.48	-5.25	-3.07
GN N N N N N N N N N N N N N N N N N N	667, 555 (4.3, 4.1)	336-832 1.49	-5.44	-3.12
Ga	650, 580 (4.5, 4.3)	410-825 1.50	-5.29	-3.02
N <sub>B</sub> N <sub>F</sub> F 7a	647, 580 (4.5, 4.3)	443-788 1.57	-5.26	-3.04
Sa	648, 574 (4.6, 4.3)	417-770 1.61	-5.27	-3.05

# Table S2 Photoelectrical properties and calculated front orbital distributions ofD-A-D and D-A compounds



<sup>*a*</sup>Estimated from the edge of both ends of the absorption band in DCM,  $E_g^{opt} = 1240/\lambda_{onset}$  [eV]. <sup>*b*</sup>From DFT calculation. For details, see the following part.





Figure S1 Normalized UV-*vis*-NIR absorption spectra of D-A and D-A-D compounds in  $CH_2Cl_2$  ( $c = 2.0 \times 10^{-5}$ ).



Figure S2 Normalized UV-*vis*-NIR absorption spectra of D-A and D-A-D compounds in CH<sub>2</sub>Cl<sub>2</sub> ( $c = 2.0 \times 10^{-5}$ ).







Figure S3 UV-vis-NIR Absorption spectra of D-A and D-A-D compounds in  $CH_2Cl_2$  ( $c = 2.0 \times 10^{-5}$ ).





Figure S4 Normalized UV-*vis*-NIR absorption spectra of 5b, 6b and 9b in different solvents ( $c = 2.0 \times 10^{-5}$ ).

#### **IV. DFT Computational detail**

The calculations were performed at TDDFT/B3LYP/6–31G(d,p) level using Gaussian 03 package<sup>S2</sup>. Ground state geometries of aza-BODIPYs were fully optimized in gas phase at DFT/B3LYP/6–31G(d,p) level using the default convergence criteria without any constraints and confirmed by frequency calculations. Front orbital levels and distributions of the optimized structure are shown in **Table S3**.

Molecule	
LUMO+1	
LUMO	

Table S3. Front orbital levels and distributions of the optimized structures

НОМО	~~~ <i>*</i> ~	
HOMO-1		
LUMO+1	-0	.06 eV
LUMO	-3	.17 eV
HOMO	-5	.37 eV
HOMO-1	-6	.25 eV
Band gap	2.	20 eV
Molecule	N N N N H F F Sa	
Dihedral	83.05 °	53.9 °
LUMO+1		
LUMO		
НОМО		
HOMO-1		
LUMO+1	-0.54 eV	-0.41 eV
LUMO	-3.05 eV	-2.94 eV
НОМО	-5.27 eV	-5.10 eV

HOMO-1	-5.55 eV	-5.45 eV
Band gap	2.22 eV	2.16 eV
Molecule		o z z z b c z z b c b c b c b c b c b c b c c b c c b c c c c c c c c c c c c c
Dihedral	89.35 °	60.45 °
LUMO+1		
LUMO		
НОМО		
НОМО-1		
LUMO+1	-0.54 eV	-0.40 eV
LUMO	-3.06 eV	-2.89 eV
HOMO	-5.29 eV	-5.00 eV
HOMO-1	-5.46 eV	-5.19 eV
Band gap	2.23 eV	2.11 eV
Molecule		
Dihedral	70.01 °	55.30 °
LUMO+1		

LUMO		
НОМО		
HOMO-1		
LUMO+1	-0.53 eV	-0.38 eV
LUMO	-3.04 eV	-2.92 eV
НОМО	-5.26 eV	-5.06 eV
HOMO-1	-5.50 eV	-5.40 eV
Band gap	2.22 eV	2.14 eV
Molecule	N, N, N, N, N, H F, F 8a	Br N H F Bb
Dihedral	83.09 °	59.77 °
LUMO+1		
LUMO		
НОМО		

НОМО-1		
LUMO+1	-0.73 eV	-0.63 eV
LUMO	-3.11 eV	-3.07eV
HOMO	-5.35 eV	-5.25 eV
HOMO-1	-5.85 eV	-5.59 eV
Band gap	2.24 eV	2.18 eV
Molecule	N.B.N. P.F. Sa	$ \begin{array}{c}                                     $
Dihedral	88.91 °	58.14 °
LUMO+1		
LUMO		
НОМО		₹ <sup>3</sup> ₹ <sup>3</sup> ₹888
НОМО-1		
LUMO+1	-1.15 eV	-1.04 eV
LUMO	-3.19 eV	-3.22 eV
НОМО	-5.44 eV	-5.44 eV
HOMO-1	-6.14 eV	-5.86 eV
Band gap	2.25 eV	2.22 eV

### **V. Electrochemical Properties**



Fig. S5. Cyclic voltammogram of 5a and 6a.

Table S	54. Energ	y levels.
---------	-----------	-----------

Dye	$E_{on}^{ox}$ $\left[\mathrm{V}\right]^{a}$	HOMO $[eV]^b$	$E_{on}^{red}$ $\left[\mathbf{V} ight]^{a}$	LUMO $[eV]^c$	$E_g^{\ cv}$ $[eV]^d$	$E_{g}^{opt}$ [eV] <sup>e</sup>	$E_g^{\ cal.}$ $\left[\mathrm{eV} ight]^d$
3a	0.32	-5.46	-0.62	-4.02	1.44	1.78	2.20
5a	0.34	-5.14	-0.67	-4.13	1.01	1.61	2.22
5b	0.55	-5.35	-0.74	-4.06	1.29	1.44	2.16
6a	0.33	-5.13	-0.68	-4.12	1.01	1.50	2.23
6b	0.53	-5.33	-0.74	-4.06	1.27	1.38	2.11

<sup>*a*</sup>  $E_{on}^{ox}$  = Initiative reduction potential,  $E_{on}^{red}$  = Initiative reduction potential. <sup>*b*</sup> HOMO = - (4.80 +  $E_{on}^{ox}$ ) (eV); <sup>*c*</sup> LUMO = - (4.80 +  $E_{on}^{red}$ ) (eV); <sup>*d*</sup>  $E_{g}^{cv} = E_{on}^{ox} - E_{on}^{red}$ ; <sup>*e*</sup>  $E_{g}^{opt} = 1240/\lambda_{onset}$  (eV).

#### VI. Reference

S1. (a) R. Gresser, H. Hartmann, M. Wrackmeyer, K. Leo and M. Riede, *Tetrahedron*, 2011, 67, 7148; (b) A. N. Amin, M. E. El-Khouly, N. K. Subbaiyan, M. E. Zandler, S. Fukuzumi and F. D'Souza, *Chem. Commun.*, 2012, 48, 206; (c) M.-Y. Chang, Y.-C. Chen and C.-K. Chan, *Tetrahedron*, 2014, 70, 2257; (d) R. Umeda, T. Mashino and Y. Nishiyama, *Tetrahedron*, 2014, 70, 4395.

S2. M. J. Frisch, G. W. Trucks, H. B. Schlegel, G. E. Scuseria, M. A. Robb, J. R. Cheeseman, V. G. Zakrzewski, J. A. Jr. Montgomery, R. E. Stratmann, J. C. Burant, S.Dapprich, J. M. Millam, A. D. Daniels, K. N. Kudin, M. C. Strain, O. Farkas, J. Tomasi, V. Barone, M. Cossi, R. Cammi, B. Mennucci, C. Pomelli, C. Adamo, S. Clifford, J. Ochterski, G. A. Petersson, P. Y. Ayala, Q. Cui, K. Morokuma, D. K. Malick, A. D. Rabuck, K. Raghavachari, J. B. Foresman, J. Cioslowski, J. V. Ortiz, B. B. Stefanov, G. Liu, A. Liashenko, P. Piskorz, I. Komaromi, R. Gomperts, R. L. Martin, D. J. Fox, T. Keith, M. A.Al-Laham, C. Y. Peng, A. Nanayakkara, C. Gonzalez, M. Challacombe, P. M. W. Gill, B. Johnson, W. Chen, M. W. Wong, J. L.Andres, C. Gonzalez, M. Head-Gordon, E. S. Replogle, J. A. Pople, Gaussian 03, revision D.01; Gaussian, Inc.: Pittsburgh, PA, 2005.

### VII. Copies of NMR spectra

#### <sup>1</sup>H NMR spectrum of **3a** in CDCl<sub>3</sub>



## <sup>13</sup>C NMR spectrum of **3a** in CDCl<sub>3</sub>



#### <sup>1</sup>H NMR spectrum of **3b** in CDCl<sub>3</sub>



### $^{13}C$ NMR spectrum of $\boldsymbol{3b}$ in CDCl\_3



#### <sup>1</sup>H NMR spectrum of **5a** in CDCl<sub>3</sub>



11.5 10.5 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0 -0.5 fl (ppm)

#### $^1\mathrm{H}$ NMR spectrum of $\mathbf{5b}$ in CDCl\_3



<sup>1</sup>H-<sup>1</sup>H COSY spectrum of **5a** in CDCl<sub>3</sub>



<sup>1</sup>H-<sup>1</sup>H COSY spectrum of **5b** in CDCl<sub>3</sub>



## <sup>1</sup>H NMR spectrum of **6a** in CDCl<sub>3</sub>



#### <sup>1</sup>H NMR spectrum of **6b** in CDCl<sub>3</sub>



#### <sup>1</sup>H NMR spectrum of **7a** in CDCl<sub>3</sub>



#### <sup>1</sup>H NMR spectrum of **7b** in CDCl<sub>3</sub>



#### <sup>1</sup>H NMR spectrum of **8a** in CDCl<sub>3</sub>



## <sup>1</sup>H NMR spectrum of **8b** in CDCl<sub>3</sub>



#### <sup>1</sup>H NMR spectrum of **9a** in CDCl<sub>3</sub>



## <sup>1</sup>H NMR spectrum of **9b** in CD<sub>3</sub>CN



#### <sup>1</sup>H NMR spectrum of **10a** in CDCl<sub>3</sub>



## $^{1}$ H NMR spectrum of **10b** in CDCl<sub>3</sub>



## <sup>1</sup>H NMR spectrum of **11a** in CDCl<sub>3</sub>



#### <sup>1</sup>H NMR spectrum of 11b in CDCl<sub>3</sub>



## <sup>1</sup>H NMR spectrum of **12** in CDCl<sub>3</sub>



#### $^{1}$ H NMR spectrum of **13** in CDCl<sub>3</sub>

